Whereas the role of Sema4D and its receptor, Plexin-B1, complex in the bone remodeling process is established8, only limited preclinical evidence in myeloma-related osteolytic bone disease is available15–17. This evidence concerns the gene SEMA4D and plasma cell myeloma.